Evidence map›Paper›PMID 35984816›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Coronavirus Disease 2019 Severity and Risk of Subsequent Cardiovascular Events.

Timothy L Wiemken, Leah J McGrath, Kathleen M Andersen, Farid Khan, Deepa Malhotra, Tamuno Alfred, Jennifer L Nguyen, Laura Puzniak, Elizabeth Thoburn, Luis Jodar and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Timothy L WiemkenPfizer Inc, Collegeville, Pennsylvania, USA.
Leah J McGrathPfizer Inc, Collegeville, Pennsylvania, USA.
Kathleen M AndersenPfizer Inc, Collegeville, Pennsylvania, USA.
Farid KhanPfizer Inc, Collegeville, Pennsylvania, USA.
Deepa MalhotraPfizer Inc, Collegeville, Pennsylvania, USA.
Tamuno AlfredPfizer Inc, Collegeville, Pennsylvania, USA.
Jennifer L NguyenPfizer Inc, Collegeville, Pennsylvania, USA.
Laura PuzniakPfizer Inc, Collegeville, Pennsylvania, USA.
Elizabeth ThoburnPfizer Inc, Collegeville, Pennsylvania, USA.
Luis JodarPfizer Inc, Collegeville, Pennsylvania, USA.
John M McLaughlinPfizer Inc, Collegeville, Pennsylvania, USA.
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLittle is known about the relationship between coronavirus disease 2019 (COVID-19) severity and subsequent risk of experiencing a cardiovascular event (CVE) after COVID-19 recovery. We evaluated this relationship in a large cohort of United States adults.

methodsUsing a claims database, we performed a retrospective cohort study of adults diagnosed with COVID-19 between 1 April 2020 and 31 May 2021. We evaluated the association between COVID-19 severity and risk of CVE >30 days after COVID-19 diagnosis using inverse probability of treatment-weighted competing risks regression. Severity was based on level of care required for COVID-19 treatment: intensive care unit (ICU) admission, non-ICU hospitalization, or outpatient care only.

resultsA total of 1 357 518 COVID-19 patients were included (2% ICU, 3% non-ICU hospitalization, and 95% outpatient only). Compared to outpatients, there was an increased risk of any CVE for patients requiring ICU admission (adjusted hazard ratio [aHR], 1.80 [95% confidence interval {CI}, 1.71-1.89]) or non-ICU hospitalization (aHR, 1.28 [95% CI, 1.24-1.33]). Risk of subsequent hospitalization for CVE was even higher (aHRs, 3.47 [95% CI, 3.20-3.76] for ICU and 1.96 [95% CI, 1.85-2.09] for non-ICU hospitalized vs outpatient only).

conclusionsCOVID-19 patients hospitalized or requiring critical care had a significantly higher risk of experiencing and being hospitalized for post-COVID-19 CVE than patients with milder COVID-19 who were managed solely in the outpatient setting, even after adjusting for differences between these groups. These findings underscore the continued importance of preventing severe acute respiratory syndrome coronavirus 2 infection from progressing to severe illness to reduce potential long-term cardiovascular complications.

Indexed as

COVID-19Heart DiseasesAdultCOVID-19 TestingHospitalizationHumansIntensive Care UnitsRetrospective StudiesSARS-CoV-2United Stateslong COVIDPASCpostacute COVID-19 syndromepost-COVID syndromeSARS-CoV-2

Identifiers

PMID35984816
PMCPMC9907540
OpenAlexW4292366935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.